October 24, 2025

Elinzanetant Approved for Menopausal Hot Flashes by FDA

Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 17, 2025

FDA Awards Nine CNPV Vouchers to Speed Reviews

Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 01, 2025

Shutdown Showdown: How Long Can Health Services Last?

Federal shutdown suspends some health services, limits National Institutes of Health research, and raises questions about Affordable Care Act subsidies, Medicaid, and public health programs.

KFF Health News

November 22, 2024

FDA Official Expects Tightened Vaccine Review

"I don't necessarily view that as a bad thing."

Reuters

November 17, 2023

FDA Approves Capivasertib With Fulvestrant for Breast Cancer

On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or m...

The ASCO Post

April 29, 2024

Exposed to Agent Orange at US Bases, Veterans Face Cancer Without VA Compensation

A veteran's struggle for recognition of health issues linked to exposure to a controversial herbicide used by the military.

KFF Health News

February 28, 2025

FDA Issues Label Change to Testosterone Drugs

The U.S. FDA has recommended new labeling changes for testosterone products based on clinical and post-market studies related to blood pressure and cardiovascular effects.

Reuters